Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 26;9(8):236.
doi: 10.3390/jcdd9080236.

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation

Nikolaos Karamichalakis  1 , Vasileios Kolovos  1 , Ioannis Paraskevaidis  1 , Elias Tsougos  1
Affiliations
Review

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation

Nikolaos Karamichalakis et al. J Cardiovasc Dev Dis. .

Abstract

Atrial arrhythmias are common in patients with diabetes mellitus (DM), and despite recent advances in pharmaceutical and invasive treatments, atrial fibrillation (AF) and atrial flutter (AFl) are still associated with substantial mortality and morbidity. Clinical trial data imply a protective effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on the occurrence of AF and AFl. This review summarizes the state of knowledge regarding DM-mediated mechanisms responsible for AF genesis and recurrence but also discusses the recent data from experimental studies, published trials and metanalyses.

Keywords: atrial fibrillation; atrial flutter; diabetes mellitus; sodium-glucose cotransporter-2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Protective mechanism of SGLT2 inhibition on atrial fibrillation. SGLT2: sodium-glucose cotransporter-2, TNF: tumor necrosis factor, IL: interleukin.
See this image and copyright information in PMC

References

    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. Ofstad A.P., Atar D., Gullestad L., Langslet G., Johansen O.E. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. Heart Fail. Rev. 2018;23:303–323. doi: 10.1007/s10741-018-9685-0. - DOI - PMC - PubMed
    1. Karam B.S., Chavez-Moreno A., Koh W., Akar J.G., Akar F.G. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc. Diabetol. 2017;16:120. doi: 10.1186/s12933-017-0604-9. - DOI - PMC - PubMed
    1. Violi F., Soliman E.Z., Pignatelli P., Pastori D. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J. Am. Heart Assoc. 2016;5:e003347. doi: 10.1161/JAHA.116.003347. - DOI - PMC - PubMed
    1. Dan G.A., Martinez-Rubio A., Agewall S., Boriani G., Borggrefe M., Gaita F., van Gelder I., Gorenek B., Kaski J.C., Kjeldsen K., et al. Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP) EP Eur. 2018;20:731–732an. doi: 10.1093/europace/eux373. - DOI - PubMed

LinkOut - more resources